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Summary
 
The role of the thymus in HIV-1 pathogenesis remains unclear. We developed an assay to
quantify the number of recent thymic emigrants in blood based on the detection of a major
excisional DNA byproduct (termed 
 
a
 
1 circle) of T cell receptor rearrangement. By studying
532 normal individuals, we found that 
 
a
 
1 circle numbers in blood remain high for the first 10–
15 yr of life, a sharp drop is seen in the late teen years, and a gradual decline occurs thereafter.
Compared with age-matched uninfected control individuals, 
 
a
 
1 circle numbers in HIV-1–
infected adults were significantly reduced; however, there were many individuals with normal
 
a
 
1 circle numbers. In 74 individuals receiving highly active antiretroviral therapy, we found no
appreciable effect on 
 
a
 
1 circle numbers in those whose baseline values were already within the
normal range, but significant increases were observed in those with a preexisting impairment.
The increases in 
 
a
 
1 circle numbers were, however, numerically insufficient to account for the
rise in levels of naive T lymphocytes. Overall, it is difficult to invoke thymic regenerative fail-
ure as a generalized mechanism for CD4 lymphocyte depletion in HIV-1 infection, as 
 
a
 
1 circle
numbers are normal in a substantial subset of HIV-1–infected individuals.
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M
 
ultiple lines of evidence indicate that HIV-1 infects
thymocytes, not only in vitro but also in a SCID
mouse implanted with human fetal thymus and liver
(SCID-hu mouse) in vivo (1–3). Autopsy studies of HIV-
1–infected individuals (4) or SIV-infected macaques (5, 6)
show both infection and altered histopathology of the thy-
mus. Evaluation of thymic function in humans would be
facilitated by noninvasive techniques to measure the output
of thymocytes from this primary lymphoid organ. In mice
given bromodeoxyuridine, cells that recently left the thy-
mus could be detected by their low-level incorporation of
this label (7); in chickens, such cells could be tracked by
the expression of the chT1 antigen (8, 9). These tech-
niques, however, are not applicable to human studies.
Computer tomography scan of the chest has been used
to correlate thymic sizes of HIV-1–infected individuals
to their CD4
 
1
 
 naive (CD45RA
 
1
 
CD62L
 
1
 
) lymphocyte
counts (10), but such an imaging technique cannot reliably
measure the true lymphoid mass of the thymus (4, 11).
As progenitor T cells undergo TCR rearrangement in
the thymus, certain chromosomal sequences are excised to
produce episomal DNA byproducts termed TCR exci-
sional circles (TRECs)
 
1
 
 (12, 13). Although TRECs are
quite stable, they are diluted out by cell division or lost
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 HAART, highly active antiviral therapy;
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excisional circles. 
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with cell death (14). Thus, the detection of TRECs in T
lymphocytes in blood could serve as a marker for recent
thymic emigrants (RTEs) (8, 9). “Recent” denotes T lym-
phocytes that have undergone no more than a few cellular
divisions since leaving the site of TCR rearrangement. It
does not necessarily reflect the time elapsed. In fact, cells
that are destined to become 
 
a/b
 
 T cells first delete the 
 
d
 
 lo-
cus from the 
 
a
 
 locus during thymic maturation (15, 16).
Furthermore, there is a preferred way of deleting the 
 
d
 
 lo-
cus to give rise to 
 
z
 
70% of  
 
a/b
 
 T cells (17). This rear-
rangement forms the 
 
d
 
Rec–
 
C
 
J
 
a
 
 coding joint in the chro-
mosomal DNA, and an 89-kb TREC (
 
a
 
1 circle) is
generated as an episomal byproduct (see Fig. 1 A). Re-
cently, Douek et al. used a quantitative competitive PCR
assay to quantify this particular TREC (18). They found
that the number of TRECs in CD4
 
1
 
 and CD8
 
1
 
 lympho-
cytes in the blood of 25 normal individuals decreased ex-
ponentially by 1–1.5 log from birth to age 73 and that the
low TREC numbers in 10 HIV-1–infected individuals
were restored upon treatment with highly active antiretro-
viral therapy (HAART). We now describe a comprehen-
sive study using a real-time PCR/molecular beacon assay
to quantify 
 
a
 
1 circles as a measure of RTEs in the blood of
532 normal persons, 171 untreated HIV-1–infected indi-
viduals, and 74 HIV-1–infected individuals whose plasma
viremia had been well suppressed by HAART.
 
Materials and Methods
 
Real-Time PCR Detection of 
 
a
 
1 Circles.
 
Genomic DNA was
extracted using TriReagent (Molecular Research Center, Inc.)
according to the manufacturer’s instructions. To detect 
 
a
 
1 cir-
cles, a molecular beacon
 
 
 
was used in combination with real-time
PCR. The method of detection using molecular beacons (19, 20)
and a fluorescence detector system (21–24) has been previously
described. Each 50-
 
m
 
l reaction contained 5 
 
m
 
l of DNA, and the
final concentration of each component was as follows: 1.0
 
3
 
 Taq-
man buffer A (Perkin-Elmer Corp.), 3.5 mM MgCl
 
2
 
,
 
 
 
0.4 pmol/
 
m
 
l of molecular beacon, 0.4 pmol/
 
m
 
l of each primer, and 1.25 U
of AmpliTaq Gold DNA Polymerase (Perkin-Elmer Corp.). The
primers (sense, 5
 
9
 
-GGATGGAAAACACAGTGTGACATGG-3
 
9
 
and antisense, 5
 
9
 
-CTGTCAACAAAGGTGATGCCACATCC-
3
 
9
 
) amplified a 208-bp product. The amplicon was sequenced
and found to contain the appropriate motifs for a recombination
signal sequence (12, 13).
A molecular beacon was included in the reaction mixture
throughout PCR to serve as a real-time detector for the ampli-
fied product. The molecular beacon was designed to recognize a
region upstream from the signal joint. This beacon was specifi-
cally designed to have a hairpin structure, with a 6-bp stem and a
26-nucleotide target recognition loop, plus a fluorophore (FAM
[6-carboxyfluorescein]) and quencher (DABCYL [4-dimeth-
ylaminophenlazo benzoic acid]) in close proximity to the two
ends of the oligonucleotide. The target recognition sequence for
the molecular beacon was 5
 
9
 
-GAGAACGGTGAATGAAGAG-
CAGACAG-3
 
9
 
.
One cycle of denaturation (95
 
8
 
C for 10 min) was performed,
followed by 45 cycles of amplification (94
 
8
 
C for 30 s, 60
 
8
 
C for 30
s, and 72
 
8
 
C for 30 s). PCR was carried out in a spectrofluoromet-
ric thermal cycler (ABI PRISM 7700; Applied Biosystems, Inc.)
that monitors changes in the fluorescence spectrum of each reac-
tion tube during the annealing phase while simultaneously carry-
ing out programmed temperature cycles. The cycle number dur-
ing PCR that yields a fluorescence intensity significantly above
the background is designated as the threshold cycle (C
 
T
 
). As
shown here (see Fig. 1 A) and reported elsewhere (21–25), the
C
 
T
 
 is directly proportional to the log of the copy number of the
target sequence in the input DNA. We have found that this 
 
a
 
1
circle assay is efficient (
 
,
 
4 h), specific (see Results and Dicus-
sion), sensitive (10 copies), dynamic (7-log range), and accurate
(10% coefficient of variance). To normalize for cell equivalents in
the input DNA, we used a separate real-time PCR/molecular
beacon assay to quantify the CCR5 coding sequence, as it is
known that this gene is present at only two copies per cell, i.e.,
there are no pseudogenes (Kostrikis, L. and D.D. Ho, personal
communication).
 
Patients.
 
HIV-1–infected individuals were considered acutely
infected if they were enrolled in treatment protocols within the
first 90 d of symptoms of their acute HIV-1 infection. If enrolled
after 90 d of symptoms, they were considered chronically in-
fected. In the studies of the effect of treatment on 
 
a
 
1 circle num-
bers, every patient was treated with a three- or four-drug combi-
nation. The regimens were standard dosages of zidovudine and
lamivudine plus ritonavir, indinavir, nelfinavir, ritonavir/saquinavir,
or abacavir/amprenavir. 13 of  the chronically infected individu-
als were treated with the combination of stavudine, lamivudine,
nelfinavir, saquinavir, and IL-2 (9 MU/day for 5 d in 6-week in-
tervals for 8 cycles after day 28).
 
Immunological and Virological Monitoring.
 
Quantitation of CD3
 
1
 
,
CD4
 
1
 
, CD8
 
1
 
, and CD45RA
 
1
 
62L
 
1
 
 subpopulations in peripheral
blood samples from HIV-1–infected individuals was done by
four-color flow cytometry using the following mAbs: anti-CD3–
PerCp (Becton Dickinson), anti-CD4–APC (Exalpha), anti-
CD8–APC (PharMingen), anti-CD45RA–FITC (Becton Dick-
inson), and anti-62L–PE (Becton Dickinson). In the lymphocyte
subsets study, a minimum of 10
 
5
 
 naive or memory cells were iso-
lated using a fluorescence-activated cell sorter, MoFLO (Cyto-
mation, Inc.). Using four-color flow cytometry, naive cells were
defined as CD45RA
 
1 
 
and CD62L
 
1
 
, whereas memory cells were
defined as CD45RO
 
1 
 
for both CD4
 
1 
 
and CD8
 
1 
 
populations.
The purity of the sorted cells was 
 
.
 
99%, as analyzed by a FACS-
Calibur™ flow cytometer (Becton Dickinson). Quantitation of
HIV-1 RNA in plasma was determined using the Roche Ultra-
sensitive Amplicor HIV-1 Monitor assay (lower limits of detec-
tion, 50 HIV-1 RNA copies/ml; Roche Molecular Systems).
 
Statistics.
 
Comparisons between groups were done by non-
parametric analysis using the Kolmogorov-Smirnov test (Stat-
view, SAS Institute, Inc.).
 
 P 
 
values over 0.05 are regarded as not
statistically significant.
 
Results and Discussion
 
Characteristics of the Real-Time PCR Assay for Measuring
 
a
 
1 Circles.
 
A real-time PCR assay with a molecular bea-
con detection system (19, 26) was used to quantify 
 
a
 
1 cir-
cles in DNA extracted from cells of interest. As shown in
Fig. 1 B, 
 
a
 
1 circles were detected in great abundance
(
 
z
 
10
 
5
 
 copies/10
 
6
 
 cells) in fetal thymic tissue but were not
detected (
 
,
 
10 copies/10
 
6
 
 cells) in nonlymphoid tissues or
immortalized cell lines. In blood CD4
 
1
 
 and CD8
 
1
 
 lym-
phocytes, 
 
a
 
1 circles were enriched in naive (defined as
CD45RA
 
1
 
CD62L
 
1
 
 cells) subpopulations by 10–50-fold 
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compared with memory (CD45RO
 
1
 
) subpopulations. The
finding of low levels of 
 
a
 
1 circles in memory cells was not
unexpected, as these cells are derived from naive cells after
antigen-induced proliferation during which TRECs are di-
luted. The specificity of the assay was further confirmed by
the absence of 
 
a
 
1 circles from sorted B cells and PBMCs of
four individuals with severe DiGeorge syndrome or SCID
(Fig. 1 B).
 
a
 
1 Circle Numbers Decline with Age.
 
The numbers of a1
circles in PBMCs were assessed in a cohort of 532 normal,
HIV-1–seronegative persons who ranged in age from in-
fants to 95-yr-olds. Fig. 2 A shows that the mean number
of a1 circles remained relatively stable at a high level of
z105/106 PBMCs for the first 10–15 yr of life. Stability of
a1 circle numbers during early childhood was confirmed
by studying sequential PBMC samples from 12 subjects fol-
lowed from birth to age 3 or 4. Not a single child showed
any significant decrease in a1 circle numbers over this pe-
riod of observation (data not shown). Given that the total
lymphocyte concentration decreases in the first 5 yr of life,
if we expressed RTE concentration as the concentration of
a1 circles per microliter of blood, then a decline in con-
centration of a1 circles per microliter of blood would be
observed with time in this age range (data not shown). Be-
tween the teen years and age 20–25, a sharp drop of z1–
1.5 logs was noted, followed by a gradual decline (down-
slope of z0.03/yr) thereafter. No differences were found
between males and females. A total decrease of z2 logs
over 10 decades was observed. It should be noted that even
persons over the age of 70 have significant numbers of a1
circles in their PBMCs. In addition, when the results in
Fig. 2 were converted to a1 circle numbers per microliter
of blood, a drop in the concentration of RTEs was seen in
the first 15 yr of life due to the known decrease in total
lymphocyte numbers during this period. Overall, these re-
sults agree with the age-related decline in thymic lymphoid
volume measured in an autopsy series (27). The multipha-
sic decrease in a1 circles over time shown in Fig. 2 A,
however, differs from the monotonic exponential decline
reported recently (18).
The same trend in age-related decline is seen when the
results are analyzed by box plots (Fig. 2 B) denoting the
90th, 75th, 50th, 25th, and 10th percentiles for each age
category. The prominent transition observed for age 16–20
is consistent with prior findings that CD41 lymphocyte re-
generation after chemotherapy is severely impaired after
the age of 20 (28, 29). Fig. 2 B also demonstrates the con-
siderable normal variation (1–1.5 logs) in a1 circle numbers
within any age category.
a1 Circle Numbers Are Reduced in a Subset of HIV-1–infected
Adults and Children. In a cross-sectional study, we com-
pared 126 HIV-1–infected adults who had never received
antiretroviral therapy with 88 age-matched seronegative
controls. Of the HIV-1–infected individuals, 65 were stud-
ied during the acute stage of HIV-1 infection, i.e., within
the first 90 d of infection. As shown in Fig. 3 A, both
acutely and chronically infected individuals have signifi-
cantly lower a1 circle numbers than controls (P , 0.05).
Many HIV-1–infected individuals, however, have a1 circle
numbers in the normal range, in contrast to the previous
suggestion that every HIV-1–infected adult has a low con-
centration of RTEs in blood (18). We performed our stud-
ies on PBMC samples, whereas the study by Douek et al.
(18) measured the number of TRECs in separated CD41
Figure 1. (A) A real-time PCR/molecular beacon
assay to detect a major excisional DNA byproduct
(a1 circle) resulting from a preferred way of deleting
the d locus from the a locus of TCR. The numbers
on the extreme right denote input copy numbers of
a1 sequences. F, fluorophore; Q, quencher; CT,
threshold cycle. (B) Levels of a1 circles in tissues,
blood, and cell lines. N and M after CD4 and CD8
represent naive (CD45RA1CD62L1) and memory
(CD45RO1) subpopulations, respectively, of 99%
purity obtained by cell sorting. Dashed line indicates
the level of assay sensitivity. BLCL, B lymphoblastoid
cell line.728 Recent Thymic Emigrants in HIV-1 Infection
and CD81 T cell populations. Note as well the absence of
supranormal a1 circle numbers from infected individuals to
support the suggestion of a “thymic rebound” that had been
raised by imaging studies on HIV-1–infected humans (10) or
histopathologic examinations of SIV-infected macaques (6).
Among HIV-1–infected individuals, no significant correla-
tion was observed between a1 circle numbers and concur-
rent CD41 lymphocyte count or plasma viral load (P .
0.05; data not shown).
A more prominent impact of HIV-1 infection on the
number of a1 circles was seen in a similar cross-sectional
comparison of 42 HIV-1–infected children (ages 0–10 yr)
with 124 age-matched seronegative controls (P , 0.05; Fig. 3
A). The HIV-1–infected children were either on no therapy
or monotherapy with a nucleoside analogue, typically zi-
dovudine. The median a1 circle value for HIV-1–infected
children was 3.7-fold lower than that in normal subjects, with
z50% having values below the normal 10th percentile. A
low a1 circle number in PBMCs of HIV-1–infected persons
could be due to either decreased thymic output or to an in-
creased rate of cell death or proliferation. No mechanistic dis-
crimination can be made from these cross-sectional analyses.
The consequence of HIV-1 infection on the number of
a1 circles was then assessed longitudinally in 16 homosex-
ual men who were enrolled in an HIV-1 natural history
cohort. They were all initially HIV-1 seronegative but be-
came infected during the course of observation. Cryopre-
served PBMC samples pre- and postseroconversion (up to
z7 yr of follow-up, and without the use of antiretroviral
drugs except for zidovudine for four individuals in their last
few time points) were assayed for a1 circles. A considerable
person-to-person variation was again noted. As exemplified
by the five cases shown in Fig. 3 B, some individuals dem-
onstrated a progressive decline in a1 circle numbers,
whereas others had sequential values that were essentially
no different from their preinfection baselines. The data
from each case were then analyzed by linear regression, and
the slope of the change in a1 circle numbers over time was
individually calculated (Fig. 3 C). Although the slope in
half of these individuals did not show an appreciable de-
cline, in the other half there was a downslope (.0.30/yr)
that was .10 times steeper than the normal rate of decline.
What might account for these dichotomous results was not
immediately evident. However, the slope of the decline in
a1 circle numbers correlated significantly with each pa-
tient’s rate of decrease of CD4 lymphocytes (R 5 0.65,
P , 0.05; Fig. 3 D). The precise mechanistic implication of
this correlation remains unclear, as it could be interpreted
to mean that the rate of loss of CD41 T cells is linked ei-
ther to a faster rate of drop in thymic output or to a faster
rate of death or proliferation for RTEs.
The Impact of HAART on the Number of a1 Circles in
HIV-1–infected Individuals. We studied the impact of
HAART on the number of a1 circles in PBMCs of 74
previously drug-naive individuals (mean age, 36; ages
ranged from 24 to 59). 27 patients began treatment within
the first 90 d of their HIV-1 infection, whereas 47 were
chronically infected for varying lengths of time. DNA ex-
tracted from sequential PBMC samples (generally $5)
from each case were assayed for a1 circles. Variable pat-
terns of response to HAART were observed, in contrast to
the nearly complete response rate previously reported (18).
As displayed in Fig. 4 A, those individuals with baseline
values of .2,200 a1 circles/106 PBMCs (the median value
for age-matched normal controls) in general did not have a
rise in a1 circle numbers while receiving HAART. In con-
trast, individuals with baseline values #2,200 typically
showed increases during treatment. These differences were
quantified by calculating the slope of the regression line for
all a1 circle data points from each individual. For example,
in the cohort of chronically infected individuals, the mean
slope of the change in a1 circles during HAART was
11.13/yr for those with a low baseline value and 20.51/
year for those with a normal baseline value (Fig. 4 A). That
the overall slope difference between individuals with low
baselines and those with normal values was statistically sig-
nificant (P , 0.05, t test) suggests that an increase in the
number of RTEs during HAART is seen primarily in indi-
viduals with an existing impairment.
The thymus is known to express high levels of CXCR4
(30–32), the major entry coreceptor for syncytium-induc-
ing (SI) strains of HIV-1 (33). Both X4 and R5 viral iso-
lates can replicate in SCID-hu mice, although X4 viruses
replicate with greater cytopathicity (30). Perhaps individu-
als with SI viruses have a lower concentration of RTEs
due to increased thymic destruction by SI viruses, especially
Figure 2. Changes in a1 cir-
cle numbers with age by (A)
scattered plot or (B) box plot
analysis. The gray line in A rep-
resents the best nonlinear fit to
the data. The number of cases in
each age category is shown at the
top of each box plot in B. The
top and bottom of each rectan-
gular box denote the 75th and
25th percentiles, respectively,
with the median shown inside
the box. Horizontal bars extend-
ing from each box represent the
90th and 10th percentiles.729 Zhang et al.
in light of the observation that such individuals have a
faster rate of CD41 T lymphocyte loss (34–36). However,
in preliminary studies, we have noted that many individuals
with low a1 circle numbers have no detectable SI viruses
in their blood (data not shown). Additional work will be
necessary to define the mechanistic pathways by which the
concentration of RTEs in blood is affected in some and
spared in others. Important clues might come from studies
to understand why HIV-1–infected children are more
likely than adults to have a lower number of RTEs. Some
have suggested that certain infected infants have an immu-
nophenotype resembling that seen in congenital athymic
defects (37, 38). The application of new assays to measure
TRECs to this clinical setting could be particularly revealing.
Increases in CD41CD45RA162L1 and CD81CD45RA1
62L1 Cells Do Not Correlate with Changes in a1 Circle Num-
bers. The sequential a1 circle numbers of eight individu-
als on an identical HAART regimen (standard dosages of
zidovudine, lamivudine, abacavir, and amprenavir; median
duration follow-up, 450 d) were converted to a1 circle
copies per volume of blood based on concurrent total lym-
phocyte counts in blood. These results were then com-
pared with the CD41 and CD81 naive (CD45RA1
CD62L1) T cell numbers (Fig. 4 B). As has been reported
(39–42), mean CD41 T lymphocyte counts increased more
significantly in the initial months of therapy, followed by a
slower rise thereafter (mean total increase of 218 cells/ml).
Mean CD41 naive cell numbers climbed steadily through-
out the treatment period (mean total increase of 93 cells/
ml), as did CD81 naive cells (mean total increase of 65
cells/ml), despite a clear drop in total CD81 T lymphocyte
counts (mean total decrease of 250 cells/ml). Six of the
eight individuals had low levels of a1 circles before therapy
(i.e., ,2,200 a1 circles/106 PBMCs). The kinetics of the
changes in a1 circles per microliter of blood did not, how-
ever, temporally correspond to those of CD41 and CD81
naive cells. There was an initial rise in the concentration of
a1 circles within the first 90 d of therapy followed by a
subsequent decrease. More importantly, the total number
of RTEs, as reflected by a1 circle measurements (,10
copies per microliter of blood), was numerically insufficient
to account for the rise seen in CD41 and CD81 naive lym-
phocytes. This could be partly explained by proliferation of
RTEs before or soon after emigration from the thymus, a
phenomenon reported to occur in the mouse (43). Alterna-
tively, this discrepancy could suggest that much of the ob-
served rise in CD45RA1CD62L1 T cells after HAART is
not due to direct outpouring from the thymus.
Conclusions. Using a simple and accurate real-time
PCR/molecular beacon assay, we have shown that the
number of RTEs in blood remains high for the first 10–15 yr
of life, followed by a sharp drop in the late teenage years
and a gradual decline thereafter. HIV-1 infection was
found to lower the concentration of RTEs in a subset of
but not all adult individuals. The rate of loss of RTEs cor-
related directly with the rate of CD41 T lymphocyte de-
cline. However, it remains unclear whether the abnormal-
ity seen in some HIV-1–infected individuals is due to
Figure 3. (A) Distribution of a1 circle numbers in uninfected and in-
fected adults and children. The number of cases studied is shown on top
of each box plot. The P values were determined by the Kolmogorov-
Smirnov method. (B) Examples of seroconverters whose longitudinal a1
circle numbers did not change with time (open symbols) and whose
numbers did (filled symbols). The slope of the change in a1 circle num-
bers with time in seroconverters (C) and its correlation with the slope of
CD4 T cell loss (D). Dashed line in C indicates 10 times the normal rate
of decline seen with aging alone.730 Recent Thymic Emigrants in HIV-1 Infection
decreased thymic output or to an increased death or prolif-
eration rate of thymic emigrants. Because many HIV-1–
infected persons had normal numbers of a1 circles, including
some with low CD41 T cell counts, it is difficult to invoke
thymic regenerative failure as a generalized mechanism for
the depletion of CD41 lymphocytes.
HAART had no appreciable effect on the number of a1
circles in those individuals whose baseline levels were already
within the normal range. On the other hand, significant in-
creases were observed in those with a preexisting impairment.
These increases, however, were numerically insufficient to
account for the rise in naive (CD45RA1CD62L1) CD41
and CD81 T lymphocytes. This finding indicates that the rise
in naive T lymphocytes during HAART may not be a direct
measure of thymic output; instead, it may largely reflect ei-
ther peripheral expansion of naive lymphocytes without a
phenotypic switch (7) or the reversion of phenotype from
memory cells (7, 44, 45). This conclusion is consistent with
the observed increase in CD45RA1CD62L1 T lymphocytes
after HAART in individuals who had been thymectomized
(11). We therefore caution against the use of such phenotypic
markers as a direct indicator of thymic output.
Figure 4. (A) Changes in a1 circle numbers in 74 individuals treated with combination antiretroviral therapy. Both acutely and chronically infected
individuals were stratified into two different categories according to their pretreatment a1 circle values: #2,200 (d) or .2,200 (s) per 106 PBMCs. (B)
HAART-associated changes in mean CD41 (j), CD81 (d), CD41CD45RA1CD62L1 (m), and CD81CD45RA1CD62L1 (r) T cell counts as well as
changes in the mean a1 circle numbers (s).
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